

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/721,774	11/26/2003	Christer Nordstedt	50291/016003	6338	
21559	7590 11/21/2006		EXAMINER		
CLARK & ELBING LLP			BORIN, MICHAEL L		
101 FEDERAL STREET BOSTON, MA 02110			ART UNIT	PAPER NUMBER	
,			1631	•	
•			DATE MAILED: 11/21/2006	DATE MAILED: 11/21/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	10/721,774	NORDSTEDT ET AL.	
Office Action Summary	Examiner	Art Unit	
	Michael Borin	1631	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period was precised to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tir will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. ED (35 U.S.C. § 133).	
Status	•		
1)⊠ Responsive to communication(s) filed on 14 Second 2a)⊠ This action is FINAL. 2b)□ This 3)□ Since this application is in condition for alloware closed in accordance with the practice under Expression in the practice of th	action is non-final. nce except for formal matters, pro		
Disposition of Claims			
4) ☐ Claim(s) 42-50 is/are pending in the application 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 42-50 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	vn from consideration.		
Application Papers	•		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine 11.	epted or b) objected to by the drawing(s) be held in abeyance. Se ion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of the certified copies of the certified copies of the prior application from the International Bureau 	s have been received. s have been received in Applicati ity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this National Stage	
Attachment(s)	«П	(070,440)	
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate	

Application/Control Number: 10/721,774

Art Unit: 1631 -

DETAILED ACTION

Status of Claims

Amendment filed 09/14/2006 is acknowledged. All previous claims are canceled and new claims 42-50 are submitted. Claims 42-50 read on the invention of the originally elected Group IV.

The new claims are directed to method of use of seven particular compounds. As applicant originally elected as species peptides comprising sequence KLVFF, the two peptides addressed in the this Office action are peptides comprising sequences VHHQKLVFFA (i.e. 12-21 fragment or peptide #12) and HHQKLVFFAE (i.e. 13-22 fragment or peptide #13).

Claim Rejections - 35 USC § 112, first paragraph

Claims 42-50 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claims contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. The new claims, to the extent they read on the elected species are directed to method of inhibiting polymerization of amyloid peptide by administering a therapeutic effective amount of compounds comprising sequences VHHQKLVFFA (i.e. 12-21 fragment or peptide #12) or HHQKLVFFAE (i.e. 13-22 fragment or peptide #13). Specification, at best, discloses that such peptides

Application/Control Number: 10/721,774

Art Unit: 1631

bind A β 1-40 (see Fig. 2A and Example 1); specification does not disclose that said peptides inhibit polymerization of amyloid peptide either *in vitro* or *in vivo*. The only demonstration of inhibit polymerization of amyloid peptide is provided for peptide AckLVFFNH2, in Example 3, pages 12-13. This is a new matter rejection.

Art Rejections

In view of the above new matter rejection, art rejection of record over Findeis is withdrawn. The Findeis reference does not teach inhibition of amyloid polymerization by peptides comprising particular sequences VHHQKLVFFA or HHQKLVFFAE as instantly claimed. In fact, to the contrary, the reference teaches that fragments having 13th residue (i.e. the leftmost H residue) fail to inhibit aggregation of amyloid peptide (see col. 57, lines 33-43 and Tab. III)

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within

Application/Control Number: 10/721,774

Art Unit: 1631

TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Borin whose telephone number is (571) 272-0713. The examiner can normally be reached on 9am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on (571) 272-0811. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Michael Borin, Ph.D.

MICHAEL BORIN, PH.D. PRIMARY EXAMINER